EDITION SPÉCIALE LEUCÉMIE AIGÜE FOCUS ASH 2013 NOUVELLE-ORLÉANS
Actualités en Onco-Hématologie à l’ASH 2013
American Society of Hematology
7 au 10 décembre 2013 – Nouvelle Orléans
Interview du Dr J.Kochenderfer
(Center for Cancer Research, National Cancer Institute, Bethesda, USA)
jQuery(document).ready(function(){
// Get the video element that we wish to control
var iframe = document.getElementById('thevideo141883046');
// Initialize Froogaloop (linked .js.min file) on the captured video
var player_141883046 = $f(iframe);
// When a link with a class of "timecode" is clicked, capture the event
jQuery('.timecode_ac_id_141883046').on('click', function (e) {
jQuery('.timecode_ac_id_141883046').removeClass('activeli');
jQuery(this).addClass('activeli'); // Prevent the default link (typically a hash) from executing
e.preventDefault();
// Get the location value from the HTML5 data parameter
var seekVal = $(this).attr('data-seek'); jQuery('.timecode-ac141883046'+seekVal).addClass('activeli');
// Using Froogaloop, trigger the SeekTo method using the captured value
player_141883046.api('seekTo', seekVal);
});
});
Selon la communication orale de S .Grupp, abs #67, « T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL », 55ème congrès de la société Américaine d’Hématologie, Nouvelle Orleans, 2013.